We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Advances in ovarian cancer treatment using a combination of statins with other drugs.
- Authors
Lei Xia; Shichao Ding; Xuezhen Wang; Xiaoyu Zhang; Lin Zhu; Hairong Zhang; Huirong Li
- Abstract
New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventional drugs has gradually become a concern. Statins, as traditional lipid-lowering drugs, play a role mainly by inhibiting HMGCR. In recent years, epidemiological studies and in vitro experiments have confirmed its anti-cancer effect, especially the effect of antiovarian cancer. Themutation rate of TP53 in ovarian cancer is as high as 95%,while HMGCR is often highly expressed in TP53 mutant tumors. However, the effect of prospective clinical trials is not ideal. This result seems understandable considering that it seems unrealistic for a lipid-lowering drug to completely inhibit tumor growth. Therefore, statins play more synergistic roles in the treatment of ovarian cancer. Because ovarian cancer is a highly heterogeneous tumor, it may be a good choice to deeply understand the mechanism of statins in the treatment of ovarian cancer and achieve precise treatment by combining it with other drugs.
- Subjects
OVARIAN cancer; CANCER treatment; STATINS (Cardiovascular agents); ANTINEOPLASTIC agents; DRUG prices; ANTILIPEMIC agents
- Publication
Frontiers in Pharmacology, 2023, Vol 13, p01
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2022.1048484